5. Conclusion
We have used a relatively simple model of hypoxia that triggers adaptive structural changes in the cerebral microvasculature to study the process of physiological angiogenesis. This model can be used to obtain mechanistic data for the processes that probably underlie the dynamic structural changes that occur in learning and the control of oxygen availability to the neurovascular unit. These mechanisms are broadly involved in a wide variety of pathophysiological processes. This is the vascular component to CNS functional plasticity, supporting learning and adaptation. The angiogenic process may wane with age, contributing to the decreasing ability to survive metabolic stress and the diminution of neuronal plasticity.
Keywords
- Vascular Endothelial Growth Factor
- Chronic Hypoxia
- Hypobaric Hypoxia
- Hypoxic Induction
- Physiological Angiogenesis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
7. References
J. C. LaManna, L.M. Vendel, and R.M. Farrell: Brain adaptation to chronic hypobaric hypoxia in rats. J.Appl.Physiol. 72:2238–2243 (1992).
N.-T. Kuo, D. Benhayon, R.J. Przybylski, R.J. Martin, and J.C. LaManna: Prolonged hypoxia increases vascular endothelial growth factor mRNA and protein in adult mouse brain. J.Appl.Physiol. 86:260–264 (1999).
J. C. Chávez, F. Agani, P. Pichiule, and J.C. LaManna: Expression of hypoxic inducible factor 1α in the brain of rats during chronic hypoxia. J.Appl.Physiol. 89:1937–1942 (2000).
P. Pichiule and J.C. LaManna: Angiopoietin-2 and rat brain capillary remodeling during adaptation and deadaptation to prolonged mild hypoxia. J.Appl.Physiol. 93:1131–1139 (2002).
M. Gassmann and R.H. Wenger: HIF-1, a mediator of the molecular response to hypoxia. News Physiol Sci 12:214–218 (1997).
J. A. Forsythe, B.-H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, and G.L. Semenza: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol.Cell.Biol. 16:4604–4613 (1996).
H. F. Bunn and R.O. Poyton: Oxygen sensing and molecular adaptation to hypoxia. Physiol.Rev. 76:839–885 (1996).
P. Pichiule, J.C. Chavez, and J.C. LaManna: Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol.Chem. 279:12171–12180 (2004).
J. C. LaManna, J.C. Chavez, and P. Pichiule: Structural and functional adaptation to hypoxia in the rat brain. J.Exp.Biol. 207:3163–3169 (2004).
S. I. Harik, R.N. Kalaria, L. Andersson, P. Lundahl, and G. Perry: Immunocytochemical localization of the erythroid glucose transporter: Abundance in tissues with barrier functions. J.Neurosci. 10:3862–3872 (1990).
S. I. Harik, W.D. Lust, S.C. Jones, K.L. Lauro, S. Pundik, and J.C. LaManna: Brain glucose metabolism in hypobaric hypoxia. J.Appl.Physiol. 79:136–140 (1995).
P. Pichiule, J.C. Chavez, and J.C. LaManna: Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J.Biol.Chem. (in press) (2004).
C. D. Funk: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871–1875 (2001).
L. Parente and M. Perretti: Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem.Pharmacol. 65:153–159 (2003).
C. D. Breder, D. Dewitt, and R.P. Kraig: Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol. 355:296–315 (1995).
N. G. Bazan: Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res. 44:2221–2233 (2003).
T. Wyss-Coray and L. Mucke: Inflammation in neurodegenerative disease—a double-edged sword. Neuron 35:419–432 (2002).
P. Teismann, M. Vila, D.K. Choi, K. Tieu, D.C. Wu, V. Jackson-Lewis, and S. Przedborski: COX-2 and neurodegeneration in Parkinson’s disease. Ann.N.Y.Acad.Sci. 991:272–277 (2003).
J. J. Hoozemans, R. Veerhuis, A.J. Rozemuller, and P. Eikelenboom: Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer’s disease. Curr.Drug Targets. 4:461–468 (2003).
P. L. McGeer and E.G. McGeer: Inflammation, autotoxicity and Alzheimer disease. Neurobiol.Aging 22:799–809 (2001).
Z. Xiang, L. Ho, J. Valdellon, D. Borchelt, K. Kelley, L. Spielman, P.S. Aisen, and G.M. Pasinetti: Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s disease neuropathology. Neurobiol.Aging 23:327–334 (2002).
M. Nagayama, K. Niwa, T. Nagayama, M.E. Ross, and C. Iadecola: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb.Blood Flow Metab 19:1213–1219 (1999).
S. Nogawa, F. Zhang, M.E. Ross, and C. Iadecola: Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 17:2746–2755 (1997).
K. Hara, D.L. Kong, F.R. Sharp, and P.R. Weinstein: Effect of selective inhibition of cyclooxygenase 2 on temporary focal cerebral ischemia in rats. Neurosci.Lett. 256:53–56 (1998).
T. Kuwano, S. Nakao, H. Yamamoto, M. Tsuneyoshi, T. Yamamoto, M. Kuwano, and M. Ono: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. 18:300–310 (2004).
M. A. Iniguez, A. Rodriguez, O.V. Volpert, M. Fresno, and J.M. Redondo: Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol.Med. 9:73–78 (2003).
J. J. Hoozemans, R. Veerhuis, I. Janssen, A.J. Rozemuller, and P. Eikelenboom: Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer’s disease. Exp.Gerontol. 36:559–570 (2001).
N. G. Kim, H. Lee, E. Son, O.Y. Kwon, J.Y. Park, J.H. Park, G.J. Cho, W.S. Choi, and K. Suk: Hypoxic induction of caspase-11/caspase-1/interleukin-1beta in brain microglia. Brain Res.Mol.Brain Res. 114:107–114 (2003).
L. Ho, H. Osaka, P.S. Aisen, and G.M. Pasinetti: Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol. 89:142–149 (1998).
C. Iadecola, K. Niwa, S. Nogawa, X. Zhao, M. Nagayama, E. Araki, S. Morham, and M.E. Ross: Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc.Natl.Acad.Sci.U.S.A 98:1294–1299 (2001).
S. J. Hewett, T.F. Uliasz, A.S. Vidwans, and J.A. Hewett: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol.Exp.Ther. 293:417–425 (2000).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this paper
Cite this paper
LaManna, J.C., Sun, X., Ivy, A.D., Ward, N.L. (2006). Is Cycloxygenase-2 (COX-2) a Major Component of the Mechanism Responsible for Microvascular Remodeling in the Brain?. In: Cicco, G., Bruley, D.F., Ferrari, M., Harrison, D.K. (eds) Oxygen Transport to Tissue XXVII. Advances in Experimental Medicine and Biology, vol 578. Springer, Boston, MA . https://doi.org/10.1007/0-387-29540-2_47
Download citation
DOI: https://doi.org/10.1007/0-387-29540-2_47
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-29543-5
Online ISBN: 978-0-387-29540-4
eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)